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Unravelling the glial response in the pathogenesis of
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ABSTRACT: Alzheimer’s disease is a progressive, incurable neurodegenerative disease targeting specific neuronal
populationswithin thebrainwhileneighboringneuronsappearunaffected.The focus fordefiningmechanismshas
therefore been on the pathogenesis in affected neuronal populations and developing intervention strategies to
prevent their cell death.However, there is growing recognitionof the importance of glial cells in thedevelopment of
pathology.Determiningexactlyhowglial cells are involved in thediseaseprocess and the susceptibility of the aging
brain provides unprecedented challenges. The present review examines recent studies attempting to unravel the
glial response during the course of disease and how this actionmay dictate the outcome of neurodegeneration. The
importance of regional heterogeneity of glial cells within the CNS during healthy aging and disease is examined to
understand how the glial cellsmay contribute to neuronal susceptibility or resilience during the neurodegenerative
process.—Alibhai, J.D.,Diack,A.B.,Manson, J.C.Unravelling theglial response in thepathogenesisofAlzheimer’s
disease. FASEB J. 32, 5766–5777 (2018). www.fasebj.org
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In 2017, Alzheimer’s disease (AD) was estimated to have
affected 50 million people worldwide, with the number
likely to double every 20 yr (1). The pathology of AD
is characterized by the accumulation of aggregates of
2 misfolded proteins, amyloid-b (Ab) and tau, in the
brain; this accumulation occurs over many decades, well
before clinical signs of disease become apparent (2, 3). The
mechanisms leading to the cerebral deposits and the re-
lationship between the misfolded proteins and clinical
disease have been the focus of decades of scientific in-
vestigation. These studies have provided potential targets
for therapeutic intervention, almost all ofwhich have been
failures (4). Thus, we still lack sufficient knowledge of
the process of neurodegeneration and its association with
the misfolded proteins to successfully interrupt or signif-
icantly attenuate its course.
Over the last decade, some insights into the un-
derstanding of AD have come from studies of the prion
diseases in which cell-to-cell transmission is achieved by
templated misfolding of the normal protein substrate by
the conformationally variant prion. AD is believed to exist
in anumberof subtypes,with experimentaldata indicating
that different conformations of Ab and tau misfolded
protein might underlie distinct pathologic phenotypes, a
phenomenon possibly analogous to the multiple strains of
thepriondiseases (5–8). In addition, themisfoldedproteins
in AD act as seeds for “prion-like” conversion of normally
folded protein to abnormal conformations (9, 10). Similar
to prions, the misfolded proteins Ab and tau are able to
induce the pathologic conformational changes in their
respective naive proteins and through this mechanism
spread within the CNS and occasionally from the periph-
ery to the brain (11). This effectwas first noted in the brains
of patients with Parkinson’s disease (PD) who received
implants of embryonic neurons that subsequently dis-
played the characteristic Lewy body inclusions seen in PD
dopaminergic neurons (12); this effect has also been shown
in animal models of AD, PD, and amyotrophic lateral
sclerosis (ALS) (13). This finding has also been reported in
subjects who underwent dura mater grafts or treatment
with human growth hormone extracted from cadaveric
human pituitaries in which foci of misfolded tau and Ab
proteins were found (in addition to the prion protein) in
their brains (14–19). However, these subjects did not
develop any clinical symptoms of AD, suggesting that
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themisfolded tau andAbproteinswere not sufficient for
the development of clinical disease.
In common with prion diseases, misfolded protein ac-
cumulation, spread, and distribution in AD has been be-
lieved to predict the regions of neurodegeneration. Thus,
the misfolded proteins, their predisposition to form amy-
loid (20), and their relationship to neurodegeneration have
been the major focus for defining AD and prion disease
mechanisms. Studies of the prion diseases have also gen-
erated new tools and robust animal models for studying
misfolded proteins. The in vitro conversion assays, in par-
ticular the protein misfolding cyclic amplification assay
first developed to study prion diseases, have now been
adapted for the study of other proteinmisfoldingdiseases,
including AD, and have greatly enhanced our ability to
study the misfolded protein in the brain (21, 22). Unlike
AD models, the prion models show all the elements of
an infectious chronic neurodegenerative process, from the
long preclinical phase through to clinical disease, neuro-
degeneration, and death. Although we recognize that
there are many differences between AD and prion dis-
eases, there are also striking similarities. The accumulation
and clearance of the misfolded protein, glial responses,
and the patterns of neurodegeneration strongly imply that
common mechanisms may operate (13, 23, 24). Thus, the
study of these diseases in parallel has the potential tomore
rapidly advance knowledge.
Studies in recent years have dramatically altered our
perception of the neurodegenerative process by examin-
ing the brain not as a single entity but in a regional and
temporal manner. Specific cell types have been examined
as well as, importantly, interactions between different cell
types. Neuronal cells and glial cell interactions within the
CNS seem to be important contributors to the process of
neurodegeneration but differ between brain regions and
vary with age (25). Understanding how these interactions
between and among different cell types in the complex
environment of the aging brain contribute to neuro-
degeneration is key to developing effective intervention
strategies for these diseases.
The common mechanisms in protein misfolding dis-
eases offer a wealth of human and animal data that pro-
vide insights into the process of neurodegeneration; thus,
intervention strategies developed for any one of these
disorders may prove to be effective across a range of
neurodegenerative conditions. Determining exactly how
the different cells of the brain orchestrate the neurode-
generative process in the complex arena of the aging
brain provides interesting challenges. The present article
discusses the role of glial cells during aging and disease
and the importance of understanding regional and cell-
specific changes.
THE COMPLEXITY OF THE BRAIN
Aging is the major risk factor for many neurodegenerative
diseases. Although the brain is one of the organs most re-
silient to aging, recent studies have highlighted numerous
aging-associated changes in all the cells of the brain. Un-
derstanding the interactions among the different cell types
during aging and in response to disease is key to defining
the effects of how andwhy aging is the principal risk factor
in many chronic neurodegenerative diseases such as AD.
Recent studies critical to this understandinghave examined
the brain not as a single compartment at one time point but
in a region-, time-, and cell-specific manner (Fig. 1).
For several decades, the neuron has been subject of the
majority of research into protein misfolding diseases. It is
nowapparent thatglial cellsarealso importantplayers in the
neurodegenerative process. Many of the proteinmisfolding
diseases (including AD, PD, ALS, and prion diseases)
demonstrate activation of glial cells concomitant with the
accumulation of themisfoldedprotein, but their precise role
in theneurodegenerativediseaseprocess isunknown.Much
evidence now exists to suggest thatmisfolded protein alone
may not be sufficient to induce neurodegeneration. We
have shown that misfolded proteins accumulate in
both degenerating and non-degenerating regions of the
brain (26). Thus, one important question is, “what leads to
resilience and susceptibility in different brain regions?”
The involvement of glial cells in the process of neuro-
degenerationwas noted as early as 1910 (27). However, it is
only relatively recently that a major investigative focus has
returned toward understanding the role of the glial cells.
Although many of the early studies concentrated on the
clinical stages of disease, current efforts to understand
the events leading to neurodegeneration have revealed the
prominence of glial cells as an early feature of the process.
Thepresent article focuseson2glial cell types,microglia and
astrocytes, because these have been the subject of a number
of recent region-specific studies. Although the disruption of
oligodendrocyte andNG2glia function has been implicated
in AD, considerably more research is required to clarify the
roles of these cells in a regional and temporal manner.
Microglia heterogeneity and AD
Microglia are the resident macrophage cells in the CNS,
representing 10% of the cells in the healthy brain. They
form a 3-dimensional lattice in which each cell inhabits a
unique nonoverlapping domain. In the normal state, they
are considered a heterogeneous population with density
differences across brain regions, with the hippocampus,
basal ganglia, substantia nigra, and olfactory telencepha-
lonmoredenselypopulated than the cerebellumandbrain
stem (28). They display region-dependent functional sig-
natures, which are enhanced further by age (29). In the
normal or resting state, theyarehighly arborized cellswith
multiple fine processes that are constantly in motion sur-
veying the parenchymal environment (30, 31) and pro-
viding trophic support to neurons (32). The processes
make contact with neurons, astrocytes, and blood vessels,
andvariation inmorphologyexistsdependingon location.
Although the importanceofvariability inmorphologyand
density between different brain regions remains unclear, a
number of distinct microglial subsets have been identi-
fied. For example, distinct subsets of microglia in specific
brain regions in murine and human tissues express dif-
fering levels of inflammatory cytokines (33). Furthermore,
microglial subpopulations have been shown to be
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differentially responsive to neurotransmitters (34), in-
dicating that microglial subtypes coordinate their func-
tions with particular neuronal populations. A more
comprehensive characterization of microglial subtypes
was performed on hippocampal slices, suggesting that
microglial diversity occurs in response to the differing
neuronal-architecture changes throughout the hippocam-
pus (35). The heterogeneity observed in distribution, mor-
phology, and function has been suggested to be
determined by environmental cues in the brain (28). A
recent study in which microglia were depleted either ge-
netically or chemically and allowed to repopulate has
provided compelling evidence that local cues are re-
sponsible for the heterogeneity (36).
Microglial cells can be easily distinguished from other
cells in the CNS by using markers such as Iba1, a protein
associated with calcium homeostasis, and CD11b, a com-
plement receptor. The expression of these markers in-
creases with microglial activation, at which point major
histocompatibility complex class II structures can also be
used as markers (31).
Microgliosis can be triggered by a pathologic insult or a
disturbance to homeostasis. The microglia adapt their
phenotype from “resting” to “activated” by modifying
both their morphology and biologic function (30, 37, 38).
Their morphology changes from that with a small cell
body and long fine processes to an amoeboid shape in
which the cell bodies enlarge and processes shorten and
cover a more limited area. Microglia activation is often
defined asM1, a proinflammatory andneurotoxic state, or
M2, ananti-inflammatoryandhealing state.However, it is
now recognized that they are much more diverse than
these previously defined M1 andM2 phenotypes (39–42).
Microglia have been shown to express pattern recogni-
tion receptors (PRRs) that respond to pathogen- or danger-
associated molecular patterns, termed PAMP or DAMP,
respectively [reviewedelsewhere (43, 44)].With thebinding
of these patterns to PRRs, an enhanced proinflammatory
response is activated, which in AD experimental models
has been shown to compromise microglial phagocytosis
(45). It has also been shown that Ab species can activate
microglia via PRRs, such as TLRs (46) or receptors for ad-
vanced glycation end-products (47). Ab derived from hu-
manADcortex has the potential to activatemicrogliawhen
injected into mice intracerebrally (48). It has also been pro-
posed that microglia can switch from one phenotype to
another (49–51) and are sensitive to signals from the pe-
ripheral immune system (52–54).
Figure 1. Unraveling disease mechanisms. To fully understand the mechanisms of disease, a combination of approaches must be used.
The most powerful approach is to utilize the different models available to us and employ a range of techniques in time-course, regional,
and cell-speciﬁc manners. Only in this way will we be able to decipher the processes of disease and identify therapeutic targets.
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Microglia in different brain regions have been shown to
respond variably to a peripheral inflammatory stimulus
(55), raising the issue of whether viral or bacterial infec-
tions thatoccurduring theprogressionofADcould lead to
region-specific activity and functional changes in micro-
glia. In addition, microglia have recently been shown to
become epigenetically modified in response to peripheral
inflammatory stimuli, thus affecting their reaction to ad-
ditional insults for up to 6 mo (56). It is also clear that a
complicated interconnected network of CNS cells con-
tributes to the activated profile adopted by microglia,
with signaling from both astrocytes and neurons having
significant impact (57–60). It is possible that neuro-
degeneration occurring in different brain regions can re-
sult in variable microglial activation states.
Reactive gliosis is a hallmark of AD, with numbers of
microglia reported to increase and correlate with disease
severity in both human AD brains and mouse models of
disease (61, 62). Microglia can be observed surrounding
amyloid plaques. Their regional distribution follows that
of the pathologic changes in AD. Recent studies indicate
that the age of the individual also plays a role inmicroglial
pathogenesis (63). The presence of microglia can be both
detrimental and beneficial toADpathogenesis. It has been
suggested that during the early phases of experimental
animal models of AD, microglial activation is potentially
beneficial to the modulation of plaque composition and
the reduction in Ab42 affinity; however, the beneficial ef-
fect is lost with aging (64). In human studies, microglial
activation is also observed at the earliest stages of clinical
disease and is associated with slower progression of clin-
ical symptoms (65). In addition, a recent study has shown
evidence for a novel disease-specific microglial subtype in
AD, which expresses a number of genes that have been
associated with genetic forms of AD, perhaps hinting at a
protective role of this subset of microglia (66).
As the disease progresses, chronic activation results in
substantial microglial proliferation, which can occur to a
differing extent in specific brain regions (67). There is also
an increase in the number and degree of expression of
inflammatory genes (68). However, a potential contribu-
tion from infiltrating peripheral cells cannot be excluded
because the blood–brain barrier is known to be compro-
mised during disease (69–72). The progressive change in
microglial phenotype is believed to have detrimental ef-
fects, such as synapse loss (73, 74), a potential role in the
spread of tau pathology (75), and damage to neurons
through release of proinflammatory factors (76, 77). A
distinct microglial subtype, termed “dark microglia,” has
also been characterized in a murine model of AD. These
cells closely surround synaptic clefts in amyloid plaques
(78) and have been proposed to play a role in the patho-
logic synaptic stripping in AD (78, 79).
Microglia pathways have been implicated in a number
of studies relating to both AD pathogenesis and risk. A
significant proportion of genes identified in genome-wide
association studies as being associated with risk for spo-
radic AD are involved in microglial functions [reviewed
elsewhere (79)]. A rare variant of a microglial-expressed
gene, TREM2, is associated with a significantly increased
risk for developing AD (80, 81). Studies have shown that
the ablation of TREM2 from microglia impairs their abil-
ities to phagocytose and increases proinflammatory cyto-
kine production. It has been hypothesized that TREM2
mutations contribute to AD pathogenesis and thus could
be a therapeutic target. However, results of studies in
various mouse models and at different stages of disease
have been inconsistent, with some suggesting a beneficial
role for TREM2 (82, 83) and others reporting a negative
effect (84). Other genes expressed by microglia that are
associated with AD susceptibility include CD33 (85, 86),
clusterin, and complement receptor 1 (86).
With the increasing identification of multiple disease-
specific subtypes of microglia, understanding how dif-
ferent microglial subtypes function and affect disease
progression will prove critically important.
Astrocyte heterogeneity and AD
Astrocytes are themost abundant glial cell in the CNS and
are distributed in a highly organized fashion with no
overlap apart from the distal tips. Astrocytes exist in great
heterogeneity, with at least 11 different astrocyte classes
having been defined to date (87, 88). Their cellular density
and morphology are believed to play a role in their con-
tribution to local functional and metabolic demands as
well as region-specific cyto-architecture. A number of
studies have examined the structure and morphology of
astrocytes at differing levels of resolution. Astrocytic pro-
cesses penetrate deep into neuropil, forming tripartite
synapses, interacting with neuronal and neighboring glial
cells, and encompassing microvessels.
Because of their diversity, astrocytes are difficult to
study. For instance, there are currently no defined molec-
ular or functional features that distinguish them. They are
most commonly defined by the expression of the molec-
ularmarker, glial fibrillary acidic protein (GFAP).Healthy
mature astrocytes express GFAP but generally at levels
below the limit of detection of immunohistochemistry,
with some exceptions (e.g., those compartmentalized to
thehippocampus).Duringneuronal injury, levels ofGFAP
rise exponentially at the site of injury, although GFAP is
only expressed in a fraction of the total cell mass (89). It is
not expressed by all astrocyte populations nor is it exclu-
sively expressed by astrocytes within the CNS. Recent
studies have begun to more precisely characterize the
variability in GFAP expression patterns among astrocyte
populations duringAD. For instance, a frame-shift variant
of GFAP has been shown to be generally increased in AD,
whereas in the hippocampus, a different GFAP isoform
was shown to be expressed exclusively in the dentate gy-
rus andCA4 subregions,with the only exceptions being in
astrocytes surrounding plaques (90). In total, 8 different
isoforms of GFAP are expressed in AD (91).
In the normal state, astrocytes exhibit a steady low
restingpotential due to their high density of voltage-gated
potassiumchannels (92); however, they are not electrically
excitable (93).More recent studies have shown differences
in the types and expression levels of potassium channels
that could account for the differences in physiologic
functionbetweenvariousbrain regions (94–96). The role of
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such ion channel diversitywithin astrocyte populations in
neurodegeneration is as yet unclear, as are the functional
consequences of astrogliosis on the distribution and pro-
portionsof ion channels. Previous studieshave shown that
the levels of astrocytic potassium channels are decreased
during AD progression, indicating a gross loss of neuro-
modulation of astrocytes (97). Astrocytes form a lattice of
gap junctions and communicate by using a chemically
excitable system. For instance, astrocytes can take up
glutamate and propagate a calcium wave to neighboring
astrocytes (98). Glutamate uptake by astrocytes is known
to prevent excitotoxicity and support excitatory neuro-
transmission of neurons; however, other studies have
shown that inflammation can exacerbate excitotoxicity
(99). Astrocytes achieve glutamate uptake primarily
throughexpressionofglutamate-aspartate transporter and
glutamate transporter 1 (GLT-1). Previous studies have
shown that glutamate-aspartate transporter is primarily
expressed in immature and developing astrocytes but
that GLT-1 exhibits regional expression differences in the
adultCNS.For instance,GLT-1 is expressedat significantly
higher levels in the brain compared with the spinal cord
(100), and differences in GLT-1 transcripts exist among
astrocyte populations within the adult brain (101), which
may lead to variation in glutamate uptake levels in dif-
ferent brain regions.
During AD progression, levels of GLT-1 are signifi-
cantly reduced in the hippocampus and cerebral cortex
(102, 103) but do not change in the prefrontal cortex (104).
Although GLT-1 expression is largely decreased during
AD, a series of alternate splice variants of GLT-1 mRNA
have been identified as being up-regulated in temporal,
frontal, and parietal cortices in human AD tissue, which
were functionally compromised for glutamate transport
(105). The significance of this observation is unclear.
The combination of reduced or compromised astrocyte
ion physiology and glutamate uptake in AD indicates a
loss of neuromodulation of astrocytes. Incidentally, as-
trocyteshavebeen shown to responddifferently tovarious
combinations of neurotransmitters in the healthy CNS;
for example, in the hippocampus, astrocytes respond to
glutamate,ATP,GABA, acetylcholine, endocannabinoids,
and prostaglandins, whereas in the cerebral cortex, as-
trocytes respond only to glutamate and norepinephrine
(106–112). These findings suggest functional differences in
the interaction between astrocytes and neurons in various
brain regions,whichmaybedifferentiallydisruptedbased
on the functional deficits occurring during AD. One par-
ticular example would be the loss of norepinephrine as
a result of the degeneration of locus coeruleus neurons
[reviewedelsewhere (113)],whichare themajorproducers
of norepinephrine for the entire CNS. This action which
would affect neuron–astrocyte communication in the ce-
rebral cortex but not in the hippocampus.
Astrocytes are also involved in the development and
support of synapses and synaptic function. Astrocytes
come into direct contact with synapses and neuronal
dendrites andcan influence synapse strengthanddendrite
maturation (114, 115). As a result, astrocytes are under-
stood to be vital formodulatingneuronal activity. It iswell
established that synaptic degeneration and loss is an early
pathology and a functional correlate of cognitive decline
(116, 117). More recent evidence has shown astrocyte at-
rophy at early stages of AD progression leading to dis-
ruptionof synapseconnectivity, synapticdysfunction,and
eventual loss (118–120).
In addition, astrocytes provide trophic support to
neurons. In particular, astrocytes have been shown to se-
crete lactate in response to glutamate release by neurons
(121). Although the prominence of lactate as a main or
secondary source of energy for neurons is under intense
debate, it is widely acknowledged that lactate plays an
important role inneuronal trophic support, at least inbrain
regions of high metabolic activity. Furthermore, glucose,
lipids, and other important neuronal metabolites are
transferred from the periphery to the CNS through the
blood–brain barrier. The role of the astrocyte in the regu-
lation and maintenance of the blood–brain barrier has
been shown to be compromised during early stages of AD
pathology (70–72, 122).
Our current understanding of astrocytes as neuro-
protective, neuromodulatory, and neurodevelopmentally
important suggests that loss of functionof these cells could
play a critical role in neurodegeneration. The majority of
literature examining the astrocyte in animal models of
disease and in human tissue has reported compromised
astrocytic function, which is likely to have a role in de-
fining the severity of neurodegeneration in the com-
promised areas. However, as discussed, astrocytes are a
heterogeneous population of cells and thus will almost
certainly exhibit differences in the type and intensity of the
disease-associated functional changes between brain re-
gions. To date, most studies examining astrocyte function
have failed to take into account the heterogeneity of as-
trocyte populations. It is certainly possible, therefore, that
astrocytes in some brain regions may act protectively,
whereas in other areas, astrocytes become functionally
compromised and contribute to neurodegeneration. As
such, ourunderstandingof the exact role of the astrocyte in
AD and how this class of cells could be targeted for ther-
apeutic intervention seems a long way off.
Oligodendrocytes
Oligodendrocytes are themyelinating cells of theCNSand
are the end-product of a cell lineage that includes NG2-
glia. The function of the mature oligodendrocytes is to
produce myelin, which insulates the axons (123). The
myelin sheath maintains the action potentials and ion
currents in the axons, thus reducing energy consumption
and increasing conductionvelocity,wherebyamyelinated
axon is more efficient at transducing a signal than an un-
myelinated one (124). The disruption of oligodendrocyte
function has been implicated in a number of disorders,
including AD, PD, multiple sclerosis, and cerebral palsy
(reviewed elsewhere (125–128)]. Any event that targets
oligodendrocytes will invariably result in demyelination.
As individuals age, myelin starts to break down, a
process that accelerates as aging progresses (129) andmay
contribute to cognitive decline and dementia. Alterations
in myelination and oligodendrocyte status have been
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observedbeforeAb and taudeposition in in vivomodels of
AD; however, these findings can vary according to the
mouse model examined (130–132).
The presence of Ab may in itself have toxic effects on
oligodendrocytes and myelin. This theory has been re-
viewed in more detail by Cai et al. (124). It is clear that
myelin disruption correlates with temporal and spatial
progression of cognitive impairment. A number of studies
haveobserveda loss of oligodendrocyte lineage cells in the
gray matter associated with amyloid plaques (133, 134).
Changes in myelin damage and oligodendrocytes in the
white matter have also been observed and have been
reviewed in detail by Nasrabady et al. (125). These alter-
ations may be caused by oxidative stress, apoptosis, or
neuroinflammationor a combination thereof (124, 125).As
yet, the mechanisms involved in oligodendrocyte dys-
function in AD have not been deciphered and remain a
potential clinical target.
Expression profiles of glial cells reveal that
regional specificity is altered with age
Age is the primary risk factor for AD, suggesting an
overlap between aging and the consequential drive to-
ward neurodegeneration in an unfortunately high pro-
portion of individuals (25). The brain is unparalleled in
its structural, cellular, and functional complexity, which
makes molecular studies of glial cells and the role they
may play in both healthy aging and during neurode-
generation extremely challenging. Although such focused
molecular studies have been useful in elucidating how
and why glial cells could be critically involved during
neurodegeneration, many are limited by studying only
a specific glial function, in a specific brain region in a
particular animal model of AD. Of course, it is well
known that glial cells do not exist in a single, one-cell-
does-all capacity but are highly heterogeneous across
the CNS. Thus, attempting to tie together the validity of
studies examining glial cell responses in the context of
the pros and cons of different animal models of disease
is nearly impossible. Recently, however, a number of
studies have overcome such problems by examining the
transcriptome of glial cells sampled across the brain
and during aging in both human tissue and in animal
models.
The elucidation of microglial regional identity first
during adulthood (135) and then during aging (136) rep-
resented landmark studies into understanding the com-
plexity of glial cells across the CNS. Grabert et al. (136)
showed that microglia exist in a regionally diverse ex-
pression pattern inwild-typemice. However, asmice age,
microglial specificity diminishes. For example, in the hip-
pocampus, the unique youthful expression signature
becomes more like that of other brain regions. This pro-
gression hints that a slow loss of specialization might
contribute todeficits during the agingprocess. This theory
was further corroborated by a study examining the ex-
pression of microglial-specific genes from the tran-
scriptome of brain regions extracted from human aging
samples (137). Other studies have examined microglia
isolated from the cerebral cortex (138) or from biopsy
material (139) and shown a similarity between themurine
and human microglial signatures, with some exceptions
between immune-related genes, which exhibit a higher
expression level in human tissue. Anotable exceptionwas
the difference in the aging profile from human cortex
compared with mouse, indicating that microglia in adult
brain regions are broadly similar in expression across
species, but human microglia age differently (138). While
recognizing that the differences in life span and time
delays in postmortem between species could result in
different profiles, there are clear commonalities being
revealed between human and animal studies.
The expression profile of astrocytes is highly heteroge-
neous in the adult brain (140), consistent with the earlier
identification of multiple classes of astrocytes (87, 88).
During aging, astrocytes have been shown to change their
gene expression profile in cell bodies within the murine
cortex, with the predominant change appearing to be an
increase in an inflammatory phenotype (141). Astrocytes
isolated from multiple brain regions in adult and aged
mice showed region-specific, age-associated changes in
the astrocyte transcriptome with many genes associated
with an inflammatory and reactive phenotype (142). The
observation is consistent with an earlier report that sug-
gested astrocyte brain region–specific alterations during
aging in humans (137). Furthermore, aged human astro-
cytes increase expression of genes typically involved in
synapse elimination during development, indicating
that the astrocyte may be critically involved in aging-
associated cognitive decline (142). Such findings have
greatly increasedourunderstandingofglial cells and their
varied expression profiles throughout the brain and dur-
ing aging. It is known, however, that only a relatively
small percentage of expressed transcripts will be trans-
lated to proteins; thus, future research will also require
advancing our understanding of the proteome heteroge-
neity. Indeed, one such study has examined the proteome
of microglia from the brains of young and aged mice but
without analyzing the varied profiles fromdifferent brain
regions (143).
EXPRESSION PROFILE OF GLIAL CELLS DURING
NEURODEGENERATIVE DISEASE
Understanding the complex glial responses in disease
ideally will utilize animal models of a progressive neuro-
degenerative disease, assessing the temporal sequence of
multiple brain region changes. Prion diseases have offered
a significant advantage in understanding glial cell re-
sponses in the context of a neurodegenerative disease.
Mice experimentally infected with prions undergo a pre-
dictable progressive neurodegenerative disease and dis-
play the complete repertoire of pathologies also found in
human prion diseases. This outcome suggests that studies
of murine prion disease may be more translatable to hu-
man disease than animal models of many other neurode-
generative diseases. Indeed, a recent study isolating
microglia from prion-infected mice over multiple time
points provides a useful resource by characterizing the
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disease-specific inflammatory response of microglia in a
progressive neurodegenerative disease (144). In animal
models of AD, a number of genes have been shown to be
differentially expressed in isolated microglia (67, 141,
145–147),many ofwhich overlapwith those identified in
prion disease (144). Among the expression of inflam-
matoryor anti-inflammatory cytokines, genes associated
with other functions, such as phagocytosis, lipid metab-
olism and lysosomal genes are also shown to be highly
activated in microglia during disease.
Transcriptomic analysis of the astrocyte in AD is re-
markably understudied. One landmark study per-
formed laser microdissection of astrocytes from brain
regions at different stages of AD as judged according
to the Braak neurofibrillary stages (148). This study
showed increasingly dissimilar, differentially expressed
genes between brain regions at early Braak stages com-
paredwith other brain regions at late stages. Among the
gene expression changes observed were many asso-
ciated with astrocyte cytoskeletal proteins consistent
with the known reactive astrogliosis that progressively
occurs during AD. Moreover, at earlier stages of AD
progression, genes involved in apoptosis and ubiquitin-
mediated proteolysis were shown to be differentially
expressed, whereas at later stages, genes involved in
tight and adherent junctions as well as many intra-
cellular signaling pathways (e.g., insulin)were shown to
differ. Many of the differentially expressed genes have
also been shown to occur in the same or other brain
regions of patients with AD at late stages of disease
(149–152). However, these data are difficult to interpret
because they represented whole tissue transcriptomes
rather than being cell type specific.
It is notable that many of these studies examine glia
either at a whole brain level or within a specific brain re-
gion. Given the current understanding of the variability
in glial gene expression among brain regions, a greater
understanding of the glial response in different brain re-
gions during the progression of disease could reveal novel
aspects and improve our understanding regarding the
potential of glial targeting for therapeutic intervention.
Indeed, a study in our laboratory showed that glial cell
responses are altered during disease progression in brain
regions that are either susceptible or show resilience to
neurodegeneration, even when the misfolded protein is
detected in all brain regions tested (26). The expression
of a number of microglial genes is differentially altered
in brain regions undergoing neurodegeneration over-
lapping with those identified in other studies of prion
disease andAD (66, 141, 144–147). Importantly, a unique
disease-specific response was also observed associated
with microglia in brain regions that show no apparent
neurodegeneration (26). This heterogeneity inmicroglial
response has also been highlighted in a recent meta-
analysis in AD, whereby distinct classes of microglia
were identified in neurodegeneration-affected brain re-
gions, including an interferon-related phenotype (153).
The role that variable glial activation states has upon
progression of neurodegeneration is unclear but could
indicate an important role of glia in defining the severity
of neurodegeneration (26).
GLIAL CELL INTERACTIONS
IN NEURODEGENERATION
During disease, microglia respond early in pathogenesis
by expressing a range of innate immune activation genes
(144). We have discussed the potential role such differing
activation states of microglia could have on the neurode-
generative process. Although astrocytes exhibit a number
of functional deficits associated with disease progression,
for many years, our understanding of the impact of
astrogliosis and astrocytic dysfunction has upon neuronal
healthhasbeen limited.Certainly, astrocytes are known to
express a number of immune-related genes and thus are
likely toplaya coordinated immune-activated response to
neurodegeneration. Studies in prion diseases have in-
dicated a mechanism by which this glial communication
could occur (Fig. 2). An early study showed that a prion-
infected neuron/astrocyte culture inoculated into mice
had chemotactic properties not present in similar prepa-
rations from control cultures (154). This finding indicates
that either, or both, the neurons or astrocytes were re-
sponsible formicroglial recruitment to the site of injection.
Another study showed that theproinflammatory cytokine
IL-1b, which could be up-regulated by many factors [in-
cludingNLRP3 inflammasomepathway activation (155)],
is important in astrogliosis activation (156), and IL-1b
synthesis ishighlyrobust inmicroglialpopulationsduring
disease (157). This finding suggests that microglial acti-
vation may be integral for astrogliosis through the secre-
tion of cytokines such as IL-1b, which in turn produces
a chemokine response to attract additional populations
of microglia, thus acting as a feedback communication
pathwaybetweenglial cellsduringdisease.Arecent study
showed that a class of activated microglia can induce an
astrogliosis response through the secretion of a combina-
tion of IL-1b, TNF-a, and C1q (76), demonstrating over-
lapping glial interaction mechanisms in AD and other
neurodegenerative diseases such as prion disease. Further-
more, such activated astrocytes are functionally impaired
andcanalso lead toneuronaldeath.This classof astrogliosis
has been termed A1, as the activation appears functionally
analogous to a “classic” activation state of microglia. Im-
portantly, suchA1astrocyteshavebeenshowntobepresent
in a range of neurodegenerative diseases, including AD.
These data suggest that resolution of glial cell activation
or disruption of glial cell interaction during disease might
be an important therapeutic intervention strategy.A recent
study showed that microglia can induce a neuroprotective
astrocytic phenotype through down-regulation of the
P2Y1 receptor (158), thereby providing a tantalizing pros-
pect of glial-targeted therapeutic intervention.
CONCLUSIONS
Our understanding of the complex process of neuro-
degeneration has, in recent years, been transformed by the
manner in which we are examining these diseases. How-
ever,weare still hampered to someextentby the limitations
of the animalmodels ofADandour ability to comparedata
among model systems, as AD models display only some
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aspects of the disease process. The understanding of com-
monalities between the different protein misfolding dis-
eases has accelerated our understanding of these chronic
neurodegenerative disease processes.
A realistic focus is on prevention of these diseases
reaching the devastating clinical manifestations of symp-
toms such as dementia, and to achieve this goal, it is im-
portant to unravel the early events of which the glial cells
are clearly a key feature. Both microglia and astrocytes
seem to have a dual role in the disease process by, on the
one hand, attempting to resolve the damage in the CNS
and, on the other hand, perhaps through loss of function
leading to the damaging inflammatory reactions that ul-
timately result in neurodegeneration. It is therefore im-
portant to tease apart these different roles with a view to
preserving and enhancing the protective functions. It is
also clear that only certain regions of the brain are vul-
nerable to the neurodegenerative process; therefore, by
examining the differences between susceptible and re-
sistant regionswithin thebrain,weare likely todefinenew
intervening targets to preserve the integrity of the brain.
We are now on the precipice of an explosion of data
aimed at understanding the complex and heterogeneous
roles of glial cell responses during aging and neuro-
degeneration by studying the brain in both a regional and
temporal manner. Large-scale genomic, proteomic, and
metabolomic data are being generated from both human
studies and from animal models. The next decade will,
with the tools nowavailable, unravel the complexity of the
pathways of neurodegenerative processes and provide
solutions to the therapeutic intervention into these dev-
astating diseases.
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